Unknown

Dataset Information

0

Anticancer Activity and Underlying Mechanism of Phytochemicals against Multiple Myeloma.


ABSTRACT: Multiple myeloma (MM)-a common hematologic malignancy of plasma cells-accounts for substantial mortality and morbidity rates. Due to the advent of novel therapies such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs), response rates were increased and free survival and overall survival have been elevated. However, adverse events including toxicity, neuropathy or continuous relapse are still problems. Thus, development of novel drugs which have less side effects and more effective is needed. This review aims to recapitulate the pharmacologic anti-MM mechanisms of various phytochemicals, elucidating their molecular targets. Keywords related to MM and natural products were searched in PUBMED/MEDLINE. Phytochemicals have been reported to display a variety of anti-MM activities, including apoptosis, cell cycle arrest, antiangiogenesis, and miRNA modulation. Some phytochemicals sensitize the conventional therapies such as dexamethasone. Also, there are clinical trials with phytochemicals such as agaricus, curcumin, and Neovastat regarding MM treatment. Taken together, this review elucidated and categorized the evidences that natural products and their bioactive compounds could be potent drugs in treating MM.

SUBMITTER: Kang B 

PROVIDER: S-EPMC6539572 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Anticancer Activity and Underlying Mechanism of Phytochemicals against Multiple Myeloma.

Kang Beomku B   Park Hyunmin H   Kim Bonglee B  

International journal of molecular sciences 20190509 9


Multiple myeloma (MM)-a common hematologic malignancy of plasma cells-accounts for substantial mortality and morbidity rates. Due to the advent of novel therapies such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs), response rates were increased and free survival and overall survival have been elevated. However, adverse events including toxicity, neuropathy or continuous relapse are still problems. Thus, development of novel drugs which have less  ...[more]

Similar Datasets

2024-07-18 | GSE272475 | GEO
| S-EPMC5968814 | biostudies-literature
| S-EPMC4834283 | biostudies-literature
| S-EPMC6742860 | biostudies-literature
2024-07-18 | GSE272474 | GEO
2024-07-18 | GSE272300 | GEO
| S-EPMC5762093 | biostudies-literature
| S-EPMC8001641 | biostudies-literature
| S-EPMC7669584 | biostudies-literature
| PRJNA1136941 | ENA